Review
Open access
Sep 2026
Immunotherapy for Newly Diagnosed Glioblastoma: Current Evidence and Future Perspectives
Background: Glioblastoma (GBM) represents the most aggressive and lethal primary malignancy of the central nervous system in adults. Although clinical trials evaluating immunotherapy strategies have increased substantially in recent years, the available evidence remains highly fragmented. This scoping review aimed to s...
R. Arend, B. Peroni, N. Lima et al.
· Journal of Personalized Medi... · 0 citations